CureVac’s lead mRNA program flunks a critical PhIIb study, raising questions for high-profile biotech unicorns
CureVac’s leading mRNA program CV9104, a prostate cancer vaccine, has failed a critical Phase IIb study. And that stinging setback for the most advanced clinical study in the field will raise fresh questions about a complex new technology that has attracted billions of dollars in investment cash.
The German biotech reported that not only did CV9104 fail the primary endpoint on improving overall survival, there was also no improvement on progression-free survival over a placebo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.